AFMD - アフィメド (Affimed N.V.) アフィメド

 AFMDのチャート


 AFMDの企業情報

symbol AFMD
会社名 Affimed N.V. (アフィメド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13 AFM11 AFM21 AFM22 AFM24 TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22 which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.   アフィメドはドイツのバイオ医薬品会社の持株会社。同社は2000年設立。ハイデルベルクのドイツがん研究センタ―で開発された技術をもとに、腫瘍細胞への自己免疫力を高める革新的なアプロ―チによるがん治療法の研究、開発、商品化に従事。開発中の製品にAFM13、AFM11、AFM21を含む。   Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives.
本社所在地 Technologiepark Im Neuenheimer Feld 582 Heidelberg 69120 DEU
代表者氏名 Thomas Hecht トーマス・ヘクト
代表者役職名 Chairman of the Supervisory Board
電話番号 +49 6221-67-4360
設立年月日 41760
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.affimed.com
nasdaq_url https://www.nasdaq.com/symbol/afmd
adr_tso
EBITDA EBITDA(百万ドル) -34.24747
終値(lastsale) 4.62
時価総額(marketcap) 288242114.16
時価総額 時価総額(百万ドル) 218.36520
売上高 売上高(百万ドル) 2.05078
企業価値(EV) 企業価値(EV)(百万ドル) 170.73193
当期純利益 当期純利益(百万ドル) -35.31480
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Affimed NV revenues decreased 25% to EUR682K. Net loss increased 3% to EUR16.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses - Bala increase of 23% to EUR13.1M (expense) Interest Expense Net increase from EUR168K to EUR466K (expense).

 AFMDのテクニカル分析


 AFMDのニュース

   Affimed N.V. (AFMD) can beat the pack with these strategies  2022/09/14 11:00:00 US Post News
As of Tuesday, Affimed N.V.’s (NASDAQ:AFMD) stock closed at $2.64, down from $2.76 the previous day. While Affimed N.V. has underperformed by -4.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -58.56%, with highs and lows ranging from $7.35 to $2.23, whereas the […]
   Affimed N.V. (NASDAQ: AFMD) Stock Forecast: Bearish Views Expect -247.84 Percent Drop In 2022  2022/09/13 17:00:00 Stocks Register
The trading price of Affimed N.V. (NASDAQ:AFMD) floating higher at last check on Tuesday, September 13, closing at $2.78, 0.54% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $2.67 and $2.795. In examining the 52-week price action we see that the … Affimed N.V. (NASDAQ: AFMD) Stock Forecast: Bearish Views Expect -247.84 Percent Drop In 2022 Read More »
   Affimed N.V. (NASDAQ: AFMD) Stock Could Be An Option To Consider  2022/08/25 15:00:00 Stocks Register
Affimed N.V. (NASDAQ:AFMD) shares, rose in value on Wednesday, 08/24/22, with the stock price up by 1.06% to the previous day’s close as strong demand from buyers drove the stock to $2.85. Actively observing the price movement in the last trading, the stock closed the session at $2.82, falling within a range of $2.78 and … Affimed N.V. (NASDAQ: AFMD) Stock Could Be An Option To Consider Read More »
   Affimed NV (AFMD) CEO Adi Hoess on Q2 2022 Results - Earnings Call Transcript  2022/08/11 16:44:08 Seeking Alpha
Affimed NV (NASDAQ:NASDAQ:AFMD) Q2 2022 Earnings Conference Call August 11, 2022, 08:30 ET Company Participants Alexander Fudukidis - Head, IR Adi Hoess - CEO Angus Smith - CFO Andreas…
   Earnings Scheduled For August 11, 2022  2022/08/11 09:09:16 Benzinga
Companies Reporting Before The Bell • Magic Software (NASDAQ: MGIC ) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. • Dingdong (Cayman) (NYSE: DDL ) is likely to report earnings for its second quarter. • Evelo Biosciences (NASDAQ: EVLO ) is projected to report earnings for its second quarter. • Affimed (NASDAQ: AFMD ) is estimated to report quarterly loss at $0.17 per share on revenue of $8.67 million. • CorEnergy Infr Trust (NYSE: CORR ) is expected to report earnings for its second quarter. • Six Flags Entertainment (NYSE: SIX ) is expected to report earnings for its second quarter. • Where Food Comes From (NASDAQ: WFCF ) is projected to report earnings for its second quarter. • BurgerFi International (NASDAQ: BFI ) is estimated to report earnings for its second quarter. • Smith-Midland (NASDAQ: SMID ) is expected to report earnings for its second quarter. • Kala Pharmaceuticals (NASDAQ: KALA ) is expected to report earnings for its second quarter.
   Affimed N.V. (AFMD) can beat the pack with these strategies  2022/09/14 11:00:00 US Post News
As of Tuesday, Affimed N.V.’s (NASDAQ:AFMD) stock closed at $2.64, down from $2.76 the previous day. While Affimed N.V. has underperformed by -4.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -58.56%, with highs and lows ranging from $7.35 to $2.23, whereas the […]
   Affimed N.V. (NASDAQ: AFMD) Stock Forecast: Bearish Views Expect -247.84 Percent Drop In 2022  2022/09/13 17:00:00 Stocks Register
The trading price of Affimed N.V. (NASDAQ:AFMD) floating higher at last check on Tuesday, September 13, closing at $2.78, 0.54% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $2.67 and $2.795. In examining the 52-week price action we see that the … Affimed N.V. (NASDAQ: AFMD) Stock Forecast: Bearish Views Expect -247.84 Percent Drop In 2022 Read More »
   Affimed N.V. (NASDAQ: AFMD) Stock Could Be An Option To Consider  2022/08/25 15:00:00 Stocks Register
Affimed N.V. (NASDAQ:AFMD) shares, rose in value on Wednesday, 08/24/22, with the stock price up by 1.06% to the previous day’s close as strong demand from buyers drove the stock to $2.85. Actively observing the price movement in the last trading, the stock closed the session at $2.82, falling within a range of $2.78 and … Affimed N.V. (NASDAQ: AFMD) Stock Could Be An Option To Consider Read More »
   Affimed NV (AFMD) CEO Adi Hoess on Q2 2022 Results - Earnings Call Transcript  2022/08/11 16:44:08 Seeking Alpha
Affimed NV (NASDAQ:NASDAQ:AFMD) Q2 2022 Earnings Conference Call August 11, 2022, 08:30 ET Company Participants Alexander Fudukidis - Head, IR Adi Hoess - CEO Angus Smith - CFO Andreas…
   Earnings Scheduled For August 11, 2022  2022/08/11 09:09:16 Benzinga
Companies Reporting Before The Bell • Magic Software (NASDAQ: MGIC ) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. • Dingdong (Cayman) (NYSE: DDL ) is likely to report earnings for its second quarter. • Evelo Biosciences (NASDAQ: EVLO ) is projected to report earnings for its second quarter. • Affimed (NASDAQ: AFMD ) is estimated to report quarterly loss at $0.17 per share on revenue of $8.67 million. • CorEnergy Infr Trust (NYSE: CORR ) is expected to report earnings for its second quarter. • Six Flags Entertainment (NYSE: SIX ) is expected to report earnings for its second quarter. • Where Food Comes From (NASDAQ: WFCF ) is projected to report earnings for its second quarter. • BurgerFi International (NASDAQ: BFI ) is estimated to report earnings for its second quarter. • Smith-Midland (NASDAQ: SMID ) is expected to report earnings for its second quarter. • Kala Pharmaceuticals (NASDAQ: KALA ) is expected to report earnings for its second quarter.
   Affimed N.V. Shares Fall 1.3% Below Previous 52-Week Low - Market Mover  2022/01/11 04:20:14 Kwhen Finance
Affimed N.V. (AFMD) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $473M. The stock is currently down 12.7% year-to-date, down 22.0% over the past 12 months, and up 109.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 54.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 51.4% The company's stock price performance over the past 12 months beats the peer average by -12.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Affimed N.V. Shares Near 52-Week Low - Market Mover  2022/01/10 08:55:49 Kwhen Finance
Affimed N.V. (AFMD) shares closed today at 0.8% above its 52 week low of $4.78, giving the company a market cap of $473M. The stock is currently down 12.7% year-to-date, down 22.0% over the past 12 months, and up 119.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 12.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 51.4% The company's stock price performance over the past 12 months beats the peer average by -12.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Affimed N.V. Shares Near 52-Week Low - Market Mover  2022/01/08 04:28:39 Kwhen Finance
Affimed N.V. (AFMD) shares closed today at 0.8% above its 52 week low of $4.78, giving the company a market cap of $495M. The stock is currently down 8.7% year-to-date, down 14.9% over the past 12 months, and up 129.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 12.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.7% lower than its 5-day moving average, 12.8% lower than its 20-day moving average, and 22.1% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 23.6% The company's stock price performance over the past 12 months beats the peer average by -27.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update  2022/01/06 11:30:00 Benzinga
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022 FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose level, and (ii) treatment of patients with more than two cycles in the investigator sponsored trial of cord blood-derived natural killer (cbNK) cells pre-complexed with AFM13 (AFM13-104) Broad development strategy launched for AFM24 enrollment initiated in three studies addressing major EGFR-expressing solid tumor indications including non-small cell lung and colorectal cancer For AFM28 a first in human study initiation is planned for second half of 2022 Cash position provides funding into 2H 2023 HEIDELBERG, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ: AFMD ), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has completed enrollment in the REDIRECT study and provided a business update.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アフィメド AFMD Affimed N.V.)

 twitter  (公式ツイッターやCEOツイッターなど)